PMID- 33621690
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2213-7173 (Electronic)
IS  - 2213-7165 (Linking)
VI  - 24
DP  - 2021 Mar
TI  - Efficacy and safety of eravacycline: A meta-analysis.
PG  - 424-428
LID - S2213-7165(21)00041-2 [pii]
LID - 10.1016/j.jgar.2021.02.009 [doi]
AB  - OBJECTIVES: This study was conducted to evaluate the efficacy and safety of 
      eravacycline, a recently approved fluorocycline for treatment of complicated 
      intra-abdominal infections (cIAIs). METHODS: PubMed, EMBASE and three trial 
      registries were searched for randomised controlled trials (RCTs) comparing the 
      efficacy and safety of eravacycline versus comparators. Odds ratios (ORs) with 
      95% confidence intervals (CIs) were estimated using random-effects models. The 
      study outcomes included clinical response, all-cause mortality and adverse events 
      (AEs). RESULTS: Three RCTs (1128 patients) with cIAIs were included. There were 
      no significant differences in clinical response in the modified 
      intention-to-treat (ITT) (OR, 0.91, 95% CI 0.62-1.35; I(2) = 0%), microbiological 
      ITT (OR, 0.93, 95% CI 0.61-1.41; I(2) = 0%) and clinically evaluable (OR, 0.98, 
      95% CI 0.55-1.75; I(2) = 0%) populations or in all-cause mortality (OR, 1.18, 95% 
      CI 0.16-8.94; I(2) = 0%). Eravacycline was associated with significantly greater 
      odds of total AEs (OR, 1.55, 95% CI 1.20-1.99; I(2) = 0%) and nausea (OR, 5.29, 
      95% CI 1.77-15.78; I(2) = 1.70%) but the increase in vomiting was non-significant 
      (OR, 1.44, 95% CI 0.73-2.86; I(2) = 1.70%). There were no significant differences 
      in serious AEs or discontinuation due to AEs. CONCLUSION: This meta-analysis of 
      RCTs found similar clinical efficacy and mortality for eravacycline compared with 
      carbapenems for treatment of cIAIs. However, the odds of total AEs and 
      specifically nausea was higher with eravacycline, while no significant 
      differences were observed in vomiting (although numerically higher), serious AEs 
      or discontinuation due to AEs.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Eljaaly, Khalid
AU  - Eljaaly K
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, 
      Jeddah, Saudi Arabia; Pharmacy Practice and Science Department, College of 
      Pharmacy, University of Arizona, Tucson, AZ, USA. Electronic address: 
      khalid-eljaaly@live.com.
FAU - Ortwine, Jessica K
AU  - Ortwine JK
AD  - Department of Pharmacy Services, Parkland Health & Hospital System, Dallas, TX, 
      USA; University of Texas Southwestern Medical School, Dallas, TX, USA.
FAU - Shaikhomer, Mohammed
AU  - Shaikhomer M
AD  - Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, 
      Jeddah, Saudi Arabia.
FAU - Almangour, Thamer A
AU  - Almangour TA
AD  - Department of Clinical Pharmacy, College of Pharmacy, King Saud University, 
      Riyadh, Saudi Arabia.
FAU - Bassetti, Matteo
AU  - Bassetti M
AD  - Infectious Diseases Clinic, Department of Health Science, University of Genoa and 
      Hospital Policlinico San Martino - IRCCS, Genoa, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210220
PL  - Netherlands
TA  - J Glob Antimicrob Resist
JT  - Journal of global antimicrobial resistance
JID - 101622459
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Carbapenems)
RN  - 0 (Tetracyclines)
RN  - 07896928ZC (eravacycline)
SB  - IM
MH  - *Anti-Bacterial Agents/adverse effects
MH  - Carbapenems
MH  - Humans
MH  - *Intraabdominal Infections/drug therapy
MH  - Tetracyclines/adverse effects
OTO - NOTNLM
OT  - Carbapenem
OT  - ESBL
OT  - Eravacycline
OT  - Intra-abdominal
OT  - Nausea
OT  - Tigecycline
EDAT- 2021/02/24 06:00
MHDA- 2021/07/06 06:00
CRDT- 2021/02/23 20:09
PHST- 2020/10/14 00:00 [received]
PHST- 2021/01/26 00:00 [revised]
PHST- 2021/02/09 00:00 [accepted]
PHST- 2021/02/24 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2021/02/23 20:09 [entrez]
AID - S2213-7165(21)00041-2 [pii]
AID - 10.1016/j.jgar.2021.02.009 [doi]
PST - ppublish
SO  - J Glob Antimicrob Resist. 2021 Mar;24:424-428. doi: 10.1016/j.jgar.2021.02.009. 
      Epub 2021 Feb 20.